NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

The company defends its cancer strategy, and says it's not a me-too developer.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

Luminice-203 yields its first topline data, but where are all the patients?